文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

揭示葛根素对抗急性肺损伤的保护机制:MST1/ERS信号作用与机制的综合探索

UNVEILING THE PROTECTIVE MECHANISMS OF PUERARIN AGAINST ACUTE LUNG INJURY: A COMPREHENSIVE EXPLORATION OF THE ROLES AND MECHANISMS OF MST1/ERS SIGNALING.
PubMed 文献 · Shock · 2024-03-21
一句话结论动物与细胞实验显示,葛根素通过抑制Mst1/ERS信号通路减轻LPS诱导的血管内皮功能障碍和急性肺损伤。

该研究为动物与细胞实验,旨在阐明Mst1/ERS信号在葛根素保护急性肺损伤(ALI)中的作用与机制。结果显示,葛根素显著保护小鼠免受LPS诱导的ALI,减轻肺间质增宽、中性粒细胞和淋巴细胞浸润、肺间质与肺泡水肿及肺细胞凋亡,并降低肺泡灌洗液和血清中TNF-α、IL-1β水平。葛根素还显著减弱LPS诱导的Mst1、GRP78、CHOP、Caspase12蛋白表达升高及ZO-1蛋白表达降低,并减轻内质网扩张与囊泡化。在HUVEC细胞中,Mst1过表达可削弱葛根素对血管内皮细胞损伤、肺损伤及内质网应激(ERS)的抑制作用。作者结论认为,Mst1/ERS信号通路在LPS诱导的血管内皮细胞功能障碍和ALI中起关键作用,葛根素通过抑制该通路发挥保护作用。

要点

  • 葛根素显著保护小鼠免受LPS诱导的ALI,减轻肺间质增宽、中性粒细胞和淋巴细胞浸润、肺间质与肺泡水肿及肺细胞凋亡。
  • 葛根素显著降低肺泡灌洗液和血清中TNF-α与IL-1β水平。
  • 葛根素显著减弱LPS诱导的肺组织中Mst1、GRP78、CHOP、Caspase12蛋白表达升高,并减轻ZO-1蛋白表达降低。
  • 在HUVEC细胞中,Mst1过表达削弱了葛根素对血管内皮细胞损伤、肺损伤及内质网应激的抑制作用。
  • 作者结论认为,Mst1/ERS信号通路在LPS诱导的血管内皮细胞功能障碍和ALI中起关键作用。

适用人群与场景

  • LPS诱导ALI的小鼠模型
  • HUVEC细胞(人脐静脉内皮细胞)

研究设计与关键结果

  • 研究类型:动物实验与细胞实验;对象为LPS诱导ALI小鼠模型和HUVEC细胞;干预为葛根素,对照为LPS诱导损伤。
  • 葛根素显著保护小鼠免受LPS诱导的ALI,减轻肺间质增宽、中性粒细胞和淋巴细胞浸润、肺间质与肺泡水肿及肺细胞凋亡。
  • 葛根素显著降低肺泡灌洗液和血清中TNF-α与IL-1β水平。
  • 葛根素显著减弱LPS诱导的肺组织中Mst1、GRP78、CHOP、Caspase12蛋白表达升高,并减轻ZO-1蛋白表达降低。
  • 葛根素明显减轻内质网扩张与囊泡化。
  • 在HUVEC细胞中,葛根素显著减轻LPS诱导的细胞活力下降和ZO-1表达降低,并减弱LPS诱导的凋亡、TNF-α与IL-1β、FD40通量及Mst1、GRP78、CHOP、Caspase12表达升高。
  • Mst1过表达削弱了葛根素对血管内皮细胞损伤、肺损伤及内质网应激的抑制作用。

证据类型、等级与局限

  • 证据类型:动物实验与细胞实验(基础研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐;作者结论认为Mst1/ERS信号通路在LPS诱导的血管内皮细胞功能障碍和ALI中起关键作用,葛根素通过抑制Mst1/ERS信号通路减轻LPS诱导的血管内皮细胞功能障碍和ALI。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Objectives: Puerarin, the principal active constituent extracted from Pueraria, is believed to confer protection against sepsis-induced lung injury. The study aimed to elucidate the role and mechanism of Mst1/ERS in puerarin-mediated protection against acute lung injury (ALI). Methods: Monolayer vascular endothelial cell permeability was assessed by gauging the paracellular flow of FITC-dextran 40,000 (FD40). ELISA was employed for the quantification of inflammatory cytokines. Identification of target proteins was conducted through western blotting. Histological alterations and apoptosis were scrutinized using hematoxylin-eosin staining and TUNEL staining, respectively. The ultrastructure of the endoplasmic reticulum was observed via transmission electron microscopy. Results: Puerarin significantly protected mice from LPS-induced ALI, reducing lung interstitial width, neutrophil and lymphocyte infiltration, pulmonary interstitial and alveolar edema, and lung apoptosis. Puerarin treatment also markedly attenuated levels of TNF-α and IL-1β in both alveolar lavage fluid and serum. Furthermore, puerarin significantly attenuated LPS-induced increases in Mst1, GRP78, CHOP, and Caspase12 protein expression and blunted LPS-induced decrease in ZO-1 protein expression in lung tissues. Puerarin obviously reduced endoplasmic reticulum expansion and vesiculation. Similarly, puerarin significantly mitigated the LPS-induced reduction in HUVEC cell viability and ZO-1 expression. Puerarin also attenuated LPS-induced increase in apoptosis, TNF-α and IL-1β, FD40 flux, and Mst1, GRP78, CHOP, and Caspase12 expression in HUVEC cells. Nevertheless, the inhibitory impact of puerarin on vascular endothelial cell injury, lung injury, and endoplasmic reticulum stress (ERS) was diminished by Mst1 overexpression. Conclusion: These findings demonstrated that the Mst1/ERS signaling pathway played a pivotal role in the development of LPS-induced vascular endothelial cell dysfunction and ALI. Puerarin exhibited the ability to attenuate LPS-induced vascular endothelial cell dysfunction and ALI by inhibiting the Mst1/ERS signaling pathway.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Chen WX, Zhang WL, Zhang HH, et al. UNVEILING THE PROTECTIVE MECHANISMS OF PUERARIN AGAINST ACUTE LUNG INJURY: A COMPREHENSIVE EXPLORATION OF THE ROLES AND MECHANISMS OF MST1/ERS SIGNALING. Shock. 2024. PMID: 38598838. doi:10.1097/SHK.0000000000002367

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。